<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Gt Biopharma Inc — News on 6ix</title>
<link>https://6ix.com/company/gt-biopharma-inc</link>
<description>Latest news and press releases for Gt Biopharma Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 11 Mar 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/gt-biopharma-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68357b1e78dffbe2df0f9312.webp</url>
<title>Gt Biopharma Inc</title>
<link>https://6ix.com/company/gt-biopharma-inc</link>
</image>
<item>
<title>GT Biopharma to Participate in the 38th Annual Roth Conference</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-to-participate-in-the-38th-annual-roth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-to-participate-in-the-38th-annual-roth-conference</guid>
<pubDate>Wed, 11 Mar 2026 11:00:00 GMT</pubDate>
<description>SAN FRANCISCO, CALIFORNIA, March 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will participate in the 38th Annual Roth Conference being held March 22-24, 2026 in Laguna Niguel, CA. 38th Annual</description>
</item>
<item>
<title>GT Biopharma Reports Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-reports-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-reports-full-year-2025-financial-results</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Phase 1 trial evaluating GTB-3650 TriKE® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose</description>
</item>
<item>
<title>GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-present-centurion-one-123000085</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-present-centurion-one-123000085</guid>
<pubDate>Tue, 17 Feb 2026 12:30:00 GMT</pubDate>
<description>SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will be participating in the Centurion One Capital 9th Annual Toronto Growth Conference on Thursday, March 5th, 2026</description>
</item>
<item>
<title>GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-announces-fda-clearance-133000596</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-announces-fda-clearance-133000596</guid>
<pubDate>Tue, 03 Feb 2026 13:30:00 GMT</pubDate>
<description>GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to extend cash runway through Q4 2026 SAN FRANCISCO, CALIFORNIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Compa</description>
</item>
<item>
<title>GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-announces-ind-submission-133000487</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-announces-ind-submission-133000487</guid>
<pubDate>Thu, 15 Jan 2026 13:30:00 GMT</pubDate>
<description>GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cash runway into Q3 2026 SAN FRANCISCO, CALIFORNIA, Jan. 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager plat</description>
</item>
<item>
<title>GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-inc-nasdaqgtbp-offers-near-term-catalyst-opportunity-with-advancing-phase-1-trials</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-inc-nasdaqgtbp-offers-near-term-catalyst-opportunity-with-advancing-phase-1-trials</guid>
<pubDate>Wed, 19 Nov 2025 13:00:00 GMT</pubDate>
<description>NAPLES, FL / ACCESS Newswire / November 19, 2025 / Patients battling aggressive blood cancers face limited treatment options and uncertain outcomes. Scientists have increasingly turned to the body's own defenses, developing therapies that empower ...</description>
</item>
<item>
<title>GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-reports-third-quarter-140000931</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-reports-third-quarter-140000931</guid>
<pubDate>Fri, 14 Nov 2025 14:00:00 GMT</pubDate>
<description>Phase 1 trial evaluating GTB-3650 TriKE® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550 TriKE® IND submission for B7H3-expressing solid tumors expected in late December 2025 or January 2026 SAN FRANCISCO, CALIFORNIA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics ba</description>
</item>
<item>
<title>GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-provides-enrollment-gtb-130000284</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-provides-enrollment-gtb-130000284</guid>
<pubDate>Thu, 23 Oct 2025 13:00:00 GMT</pubDate>
<description>The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing advancement into Cohort 4 with a dose of 10 ug/kg/day Actively screening patients for Cohort 4; anticipate initiation of dosing in the coming weeks Cohort 4 dose is potentially more reflective of the clinical efficacy threshold given positive trend in observations on multiple immunological biomarkers from the previous six patients in Cohorts 1 through 3, the</description>
</item>
<item>
<title>GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-participate-centurion-one-130000093</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-participate-centurion-one-130000093</guid>
<pubDate>Mon, 06 Oct 2025 13:00:00 GMT</pubDate>
<description>SAN FRANCISCO, CALIFORNIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will be participating in the Centurion One Capital 3rd Annual Bahamas Summit at the Rosewood Baha Mar Hotel from Tue</description>
</item>
<item>
<title>GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-participate-h-c-110000164</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-participate-h-c-110000164</guid>
<pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
<description>The Company is available for one-on-one meetings at the H.C. Wainwright Conference September 8-10, 2025 in New York City Phase 1 trial evaluating GTBP-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to enroll as expected, and the Company remains on track to release initial results from multiple dose cohorts later in 2025 Company remains on track for GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors in Q4 2025 SAN</description>
</item>
<item>
<title>GT Biopharma Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-reports-second-quarter-200500537</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-reports-second-quarter-200500537</guid>
<pubDate>Thu, 14 Aug 2025 20:05:00 GMT</pubDate>
<description>GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in the study; initial Phase 1 data expected later in 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q4 2025; recent peer-reviewed publication highlights the pre-clinical anti-tumor activity of GTB-5550 against head and</description>
</item>
<item>
<title>GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-advances-cohort-3-110000640</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-advances-cohort-3-110000640</guid>
<pubDate>Mon, 11 Aug 2025 11:00:00 GMT</pubDate>
<description>The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observedThe company plans on releasing initial Phase 1 results later in 2025 following completion of additional dose cohorts SAN FRANCISCO, CALIFORNIA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovati</description>
</item>
<item>
<title>GT Biopharma Appoints New Member to its Board of Directors</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-appoints-member-board-130000414</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-appoints-member-board-130000414</guid>
<pubDate>Fri, 13 Jun 2025 13:00:00 GMT</pubDate>
<description>SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors. “We are very pleased to welcome David to the Board of Directors. David is an experienced senior executive with global connections and a</description>
</item>
<item>
<title>GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-advances-gtb-3650-130000566</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-advances-gtb-3650-130000566</guid>
<pubDate>Mon, 19 May 2025 13:00:00 GMT</pubDate>
<description>Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results from Phase 1 later in 2025 following completion of additional dose cohorts. SAN FRANCISCO, CALIFORNIA, May 19, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pr</description>
</item>
<item>
<title>GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-participate-10th-anniversary-120000289</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-participate-10th-anniversary-120000289</guid>
<pubDate>Tue, 04 Mar 2025 12:00:00 GMT</pubDate>
<description>SAN FRANCISCO, CALIFORNIA, March 04, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that Jeffrey Miller, MD1 from the University of Minnesota Medical School2 will participate as an expert speaker at the 10th Anniversary of the Innate Killer Summit being held March 3-5, 2025 in San D</description>
</item>
<item>
<title>GT Biopharma Announces Exercise of Warrants</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-announces-exercise-warrants-190000032</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-announces-exercise-warrants-190000032</guid>
<pubDate>Tue, 25 Feb 2025 19:00:00 GMT</pubDate>
<description>SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (“NK”) cell engager platform, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 302,069 shares of its common stock having an exercise price of $4.35 per shar</description>
</item>
<item>
<title>GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-announces-request-withdrawal-120000641</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-announces-request-withdrawal-120000641</guid>
<pubDate>Tue, 25 Feb 2025 12:00:00 GMT</pubDate>
<description>SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (“NK”) cell engager platform, today announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission (“SEC”) with respect to the withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-2</description>
</item>
<item>
<title>GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-announces-first-patient-dosed-in-phase-1-trial-of-gtb-3650-second-generation-trike-for-the-treatment-of-hematologic-malignancies</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-announces-first-patient-dosed-in-phase-1-trial-of-gtb-3650-second-generation-trike-for-the-treatment-of-hematologic-malignancies</guid>
<pubDate>Mon, 27 Jan 2025 05:00:00 GMT</pubDate>
<description>Initial data from the Phase 1 trial expected in 2025 SAN FRANCISCO, CALIFORNIA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ:</description>
</item>
<item>
<title>GT Biopharma Reports Third Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-reports-third-quarter-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-reports-third-quarter-2024-financial-results</guid>
<pubDate>Thu, 14 Nov 2024 05:00:00 GMT</pubDate>
<description>GTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for treatment</description>
</item>
<item>
<title>GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-reports-second-quarter-2024-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/gt-biopharma-inc/news/gt-biopharma-reports-second-quarter-2024-financial-results-and-provides-corporate-update</guid>
<pubDate>Wed, 14 Aug 2024 04:00:00 GMT</pubDate>
<description>GTB-3650 TriKE® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE® IND submission for treatment of B7H3</description>
</item>
</channel>
</rss>